Doripenem

Doripenem is a carbapenem antibiotic that is marketed under the trade name Doribax by Janssen Pharmaceutica. It is primarily used in the treatment of bacterial infections that are severe or life-threatening.

History

Doripenem was approved by the FDA in 2007. It was developed by Shionogi Inc., a Japanese pharmaceutical company, and later licensed to Janssen Pharmaceutica, a division of Johnson & Johnson.

Medical uses

Doripenem is used to treat a variety of bacterial infections, including pneumonia, urinary tract infections, and intra-abdominal infections. It is also used in the treatment of nosocomial infections, which are infections that are acquired in hospitals or other healthcare facilities.

Mechanism of action

Doripenem works by inhibiting the synthesis of the bacterial cell wall, leading to cell death. It is a broad-spectrum antibiotic, meaning it is effective against a wide range of bacteria.

Side effects

Common side effects of doripenem include nausea, diarrhea, headache, and rash. In rare cases, it can cause serious side effects such as anaphylaxis, a severe allergic reaction.

Resistance

Like other antibiotics, the effectiveness of doripenem can be reduced by antibiotic resistance. This occurs when bacteria evolve mechanisms to survive exposure to the antibiotic.

See also

• Carbapenem
• Antibiotic resistance
• Nosocomial infection

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian